<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18066" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Azithromycin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sandman</surname>
            <given-names>Zachary</given-names>
          </name>
          <aff>Touro College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Iqbal</surname>
            <given-names>Omar A.</given-names>
          </name>
          <aff>University of Medicine &#x00026; Health Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zachary Sandman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omar Iqbal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18066.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Azithromycin is an antimicrobial medication in the macrolide class used to treat and manage bacterial infections, including community-acquired pneumonia and sexually transmitted diseases. The disorders treated by azithromycin are important causes of infectious disease morbidity and mortality in the United States. This activity reviews the indications, contraindications, mechanism of action, and toxicities of azithromycin therapy in the clinical setting, as well as important prescribing and management considerations for the healthcare team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of azithromycin.</p></list-item><list-item><p>Describe the adverse effects and contraindications of azithromycin.</p></list-item><list-item><p>Evaluate&#x000a0;the appropriate monitoring of azithromycin therapy and its toxicities.</p></list-item><list-item><p>Review considerations relevant to the interprofessional team and discuss strategies for enhancing patient outcomes and care coordination.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18066&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18066">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18066.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Azithromycin is a broad-spectrum macrolide antimicrobial among the most prescribed antimicrobial drugs in the United States. It is a erythromycin derivative with greatly enhanced activity against gram-negative bacteria (including Enterobacteriaceae) and provides coverage of many gram-positive organisms.<xref ref-type="bibr" rid="article-18066.r1">[1]</xref><xref ref-type="bibr" rid="article-18066.r2">[2]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>As an inhibitor of bacterial protein synthesis (rather than a peptidoglycan cell-wall inhibitor like beta-lactam agents), azithromycin is effective against many &#x0201c;atypical&#x0201d; bacteria such as chlamydiae (eg, <italic toggle="yes">Chlamydia trachomatis </italic>and <italic toggle="yes">Chlamydophila psittaci</italic>), legionella (ie, <italic toggle="yes">Legionella pneumophila</italic>), mycoplasma (eg, <italic toggle="yes">Mycoplasma pneumoniae</italic>), and mycobacteria (eg, <italic toggle="yes">Mycobacterium avium</italic>).<xref ref-type="bibr" rid="article-18066.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Together with its activity against <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Hemophilus influenzae</italic>, and <italic toggle="yes">Moraxella catarrhalis</italic>, azithromycin is indicated&#x02014;and FDA-approved&#x02014;for treating community-acquired pneumonia (CAP).<xref ref-type="bibr" rid="article-18066.r4">[4]</xref> &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Azithromycin has also been approved for use in other upper respiratory infectious processes, including acute otitis media and acute exacerbation of chronic obstructive pulmonary disease (COPD).<xref ref-type="bibr" rid="article-18066.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Additionally, azithromycin has&#x000a0;approval for the treatment of pharyngitis caused by <italic toggle="yes">Streptococcus pyogenes</italic>&#x000a0;as an alternative to a beta-lactam agent; skin or skin structure infection due to <italic toggle="yes">S. pyogenes</italic>, <italic toggle="yes">Streptococcus agalactiae</italic>, or <italic toggle="yes">Staphylococcus aureus</italic>; <italic toggle="yes">&#x000a0;</italic>M<italic toggle="yes">. avium</italic> complex (MAC) infection treatment and prophylaxis for patients with advanced acquired immunodeficiency syndrome (AIDS); and sexually transmitted infections including chlamydia, gonococcal disease, chancroid (caused by <italic toggle="yes">Hemophilus ducreyi</italic>), and <italic toggle="yes">Mycoplasma genitalium</italic>.<xref ref-type="bibr" rid="article-18066.r6">[6]</xref><xref ref-type="bibr" rid="article-18066.r7">[7]</xref><xref ref-type="bibr" rid="article-18066.r8">[8]</xref><xref ref-type="bibr" rid="article-18066.r9">[9]</xref><xref ref-type="bibr" rid="article-18066.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Azithromycin also has efficacy against some protozoal organisms such as <italic toggle="yes">Babesia sp.</italic> (eg, <italic toggle="yes">B. microti</italic>), <italic toggle="yes">Plasmodium sp. </italic>(ie, malaria), and <italic toggle="yes">Toxoplasma gondii</italic> and is sometimes used off-label for the treatment of these parasitic diseases in combination with antiprotozoal drugs (eg, atovaquone).<xref ref-type="bibr" rid="article-18066.r18">[11]</xref><xref ref-type="bibr" rid="article-18066.r19">[12]</xref><xref ref-type="bibr" rid="article-18066.r20">[13]</xref></p>
          </list-item>
          <list-item>
            <p>The role of azithromycin in the treatment of viral infections, including the respiratory syncytial virus and novel coronavirus SARS-CoV-2, is indeterminate.<xref ref-type="bibr" rid="article-18066.r23">[14]</xref><xref ref-type="bibr" rid="article-18066.r24">[15]</xref><xref ref-type="bibr" rid="article-18066.r25">[16]</xref><xref ref-type="bibr" rid="article-18066.r26">[17]</xref><xref ref-type="bibr" rid="article-18066.r27">[18]</xref><xref ref-type="bibr" rid="article-18066.r26">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Lastly, azithromycin is also used off-label as long-term prophylaxis for bronchiolitis obliterans (BO) in patients who have undergone lung transplantation.<xref ref-type="bibr" rid="article-18066.r13">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18066.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Like other macrolide antimicrobials, azithromycin binds to the 23S portion of the 50S bacterial ribosomal subunit. It inhibits bacterial protein synthesis by preventing the transit of aminoacyl-tRNA and the growing protein through the ribosome. Azithromycin is less prone to disassociation from the gram-negative ribosome than erythromycin, conferring its greater efficacy against gram-negative pathogens.<xref ref-type="bibr" rid="article-18066.r28">[20]</xref>&#x000a0;Like other macrolides and protein-synthesis inhibitors, azithromycin primarily acts as a bacteriostatic agent, inhibiting bacterial growth rather than directly killing organisms. However, especially at higher doses, azithromycin has been shown to have a bactericidal effect against certain bacteria, such as streptococci and <italic toggle="yes">H. influenzae</italic>.<xref ref-type="bibr" rid="article-18066.r29">[21]</xref><xref ref-type="bibr" rid="article-18066.r30">[22]</xref></p>
        <p>Pharmacokinetically, azithromycin rapidly moves from the bloodstream into tissues and, once there, readily crosses cellular membranes, allowing efficacy against intracellular pathogens.<xref ref-type="bibr" rid="article-18066.r28">[20]</xref><xref ref-type="bibr" rid="article-18066.r30">[22]</xref>&#x000a0;In non-bacterial organisms (ie, apicomplexan parasites such as <italic toggle="yes">Babesia sp.</italic>, <italic toggle="yes">Plasmodium sp.</italic>, and <italic toggle="yes">Toxoplasma sp.</italic>), azithromycin inhibits the 50S ribosome found in the parasite apicoplast, an endosymbiosis-derived organelle with bacteria-like protein-synthesis machinery that performs critical metabolic functions.<xref ref-type="bibr" rid="article-18066.r31">[23]</xref><xref ref-type="bibr" rid="article-18066.r32">[24]</xref></p>
        <p>In addition to azithromycin&#x02019;s antimicrobial activity, it is also a potent immunomodulator shown to markedly reduce airway neutrophilia, IL-8 gene expression, and C-reactive protein levels in lung transplant recipients.<xref ref-type="bibr" rid="article-18066.r33">[25]</xref>&#x000a0;Azithromycin has in vitro antiviral properties, which has created interest in the experimental treatment of SARS-CoV-2. By inducing the expression of RIG-I-like helicases, azithromycin enhanced the rhinovirus-induced expression of interferons in&#x000a0;cultured cells of&#x000a0; COPD patients but not in cultured cells of healthy patients in vitro.<xref ref-type="bibr" rid="article-18066.r35">[26]</xref></p>
      </sec>
      <sec id="article-18066.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Azithromycin is available for both oral and parenteral (intravenous) administration. The extended-release formulation of azithromycin has been discontinued. The usual dose is 250 mg or 500 mg, given once daily for 3 to 5 days, and in severe infections, a higher dose is used. A single dose is occasionally used at 30 mg/kg for otitis media and at 1 g for adults with Chlamydia.</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral formulations include tablets (250 mg, 500 mg), packets&#x000a0;(1 gram dissolved in &#x000bc; cup or 60 ml of water), and suspension for reconstitution (100 mg/5 ml, 200 mg/5 ml). Dosing can be administered with or without food.</p>
          </list-item>
          <list-item>
            <p>Intravenous (IV) azithromycin is available in a 500 mg preservative-free solution for reconstitution. It should be infused over at least 60 minutes, and azithromycin administration should not be via intramuscular injection or IV bolus.</p>
          </list-item>
          <list-item>
            <p>The ophthalmic solution (1%) is available in a 2.5 ml bottle used in bacterial conjunctivitis.</p>
          </list-item>
        </list>
        <p>Azithromycin demonstrates excellent tissue penetration and intracellular accumulation. Metabolism is hepatic, and excretion is mainly biliary.<xref ref-type="bibr" rid="article-18066.r38">[27]</xref>&#x000a0;Its long half-life and extensive tissue and intracellular distribution permit once-daily dosing and a shorter course of treatment than other antimicrobials (eg, treatment of chlamydia infection with a single administration of 1 g of azithromycin versus 100 mg of doxycycline twice daily for&#x000a0;7 days). Azithromycin may be administered to patients with renal disease or failure without regard for creatinine clearance. No dose adjustment is usually necessary.<xref ref-type="bibr" rid="article-18066.r37">[28]</xref></p>
      </sec>
      <sec id="article-18066.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Azithromycin is generally considered a safe antimicrobial agent, and only a few patients discontinue azithromycin due to adverse effects.<xref ref-type="bibr" rid="article-18066.r44">[29]</xref>&#x000a0;It is also considered safer and has fewer cardiac adverse effects than other macrolides (ie, erythromycin and clarithromycin).</p>
        <list list-type="bullet">
          <list-item>
            <p>Like other macrolides, Azithromycin can cause QTc prolongation and has been associated with torsades de pointes and polymorphic ventricular tachycardia.<xref ref-type="bibr" rid="article-18066.r45">[30]</xref>&#x000a0;In a large retrospective cohort study, azithromycin use correlated with a small but significant absolute increase in cardiovascular death as well as an increased risk of cardiovascular death relative to amoxicillin. These results were most pronounced among those patients with the highest baseline cardiovascular risk.<xref ref-type="bibr" rid="article-18066.r45">[30]</xref>&#x000a0;However, another large cohort study failed to detect an increased risk of death from cardiovascular causes in a population of young and middle-aged adults.<xref ref-type="bibr" rid="article-18066.r46">[31]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Azithromycin is also rarely associated with hepatotoxicity, consisting mainly of hepatocellular injury within 1&#x000a0;to 3 weeks of medication use. Clinical features of hepatotoxicity include cholestatic jaundice and elevated transaminase concentrations.<xref ref-type="bibr" rid="article-18066.r47">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Like&#x000a0;other macrolides, gastrointestinal adverse effects such as nausea and diarrhea are commonly reported for azithromycin. All macrolides exhibit dose-dependent activation of intestinal motilin receptors, stimulating gastric motility. (Clinicians widely prescribe erythromycin for treating gastroparesis due to this mechanism.)<xref ref-type="bibr" rid="article-18066.r48">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Life-threatening hypersensitivity reactions to azithromycin, such as anaphylaxis and Stevens-Johnson syndrome (SJS), are extremely unusual.<xref ref-type="bibr" rid="article-18066.r49">[34]</xref><xref ref-type="bibr" rid="article-18066.r50">[35]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Macrolides also correlate with the development of <italic toggle="yes">Clostridioides difficile </italic>infection but to a lesser degree than other common antimicrobial classes (eg, clindamycin, fluoroquinolones, and cephalosporins).<xref ref-type="bibr" rid="article-18066.r51">[36]</xref><xref ref-type="bibr" rid="article-18066.r52">[37]</xref><xref ref-type="bibr" rid="article-18066.r53">[38]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18066.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Azithromycin is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylaxis or SJS) to azithromycin or another macrolide antimicrobial. In addition, clinicians should be cautious regarding the concomitant use of azithromycin and other medications that prolong the QTc interval (eg, antipsychotics).</p>
          </list-item>
          <list-item>
            <p>Azithromycin is contraindicated for patients taking the first-generation antipsychotic pimozide. Macrolide antimicrobials inhibit CYP3A4, the same cytochrome that metabolizes pimozide; concomitant use of azithromycin with pimozide can cause dangerous plasma concentrations of pimozide, leading to QTc prolongation and, potentially, lethal arrhythmias. While azithromycin is a poor inhibitor of CYP3A4 relative to other macrolides, avoiding this interaction is still advisable.<xref ref-type="bibr" rid="article-18066.r55">[39]</xref><xref ref-type="bibr" rid="article-18066.r56">[40]</xref></p>
          </list-item>
          <list-item>
            <p>Additionally, azithromycin is an inhibitor of p-glycoprotein/ABCB1, a cell membrane glycoprotein transporter.&#x000a0;Drugs that are substrates of P-glycoprotein, particularly those that are also substrates of CYP3A4, may represent a relative contraindication to azithromycin. Examples include colchicine and small-molecule calcitonin gene-related peptide (CGRP) antagonists.<xref ref-type="bibr" rid="article-18066.r57">[41]</xref><xref ref-type="bibr" rid="article-18066.r58">[42]</xref></p>
          </list-item>
          <list-item>
            <p>Azithromycin effectively preserves FEV and ameliorates bronchiolitis obliterans (BO) with no effect on overall survival in lung transplant patients; however, a study comparing azithromycin with placebo for the prevention of BO in hematopoietic stem cell transplant (HSCT) recipients demonstrated decreased BO-free and overall survival with azithromycin.<xref ref-type="bibr" rid="article-18066.r60">[43]</xref>&#x000a0;Hence, long-term azithromycin prophylaxis in HSCT recipients is inadvisable.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18066.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Most courses of treatment with azithromycin are short, and adverse effects requiring therapy adjustment or discontinuation of azithromycin are rare.<xref ref-type="bibr" rid="article-18066.r44">[29]</xref>&#x000a0;Azithromycin should be immediately discontinued if signs of hepatotoxicity develop (eg, jaundice or elevated transaminases). For patients receiving long-term azithromycin prophylaxis (eg, AIDS patients for MAC prophylaxis or lung transplant recipients for BO prophylaxis), many patients experience gastrointestinal adverse effects, especially at higher doses (eg, 600 mg or 1200 mg). In these patients, reducing the dose or twice-daily dosing&#x000a0;may&#x000a0;be a consideration.<xref ref-type="bibr" rid="article-18066.r62">[44]</xref><xref ref-type="bibr" rid="article-18066.r63">[45]</xref></p>
      </sec>
      <sec id="article-18066.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Azithromycin, like other macrolides, is associated with QTc prolongation. Particularly in patients with a known history of QTc interval perturbation, cardiac arrhythmia, or concomitant use of other medications associated with QTc prolongation, azithromycin can result in dangerous or potentially lethal arrhythmias such as torsades de pointes. In animal studies, although azithromycin was associated with similar QTc prolongation compared to other macrolides, azithromycin seemed to have a smaller proarrhythmic effect.<xref ref-type="bibr" rid="article-18066.r64">[46]</xref>&#x000a0;While significant hepatoxicity resulting from azithromycin is relatively rare, macrolides are an established cause of mixed hepatocellular/cholestatic drug-induced liver injury. With prompt discontinuation of azithromycin, liver injury is almost always reversible with minimal residual impairment. Often, azithromycin-induced hepatotoxicity has associated immunoallergic features such as rash, fever, and eosinophilia. Severe forms of immunoallergic reaction, such as anaphylaxis, SJS, and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare.<xref ref-type="bibr" rid="article-18066.r65">[47]</xref>&#x000a0;Gastrointestinal toxicity is common but typically mild, and most patients complete the prescribed course of azithromycin. This toxicity stems largely from azithromycin&#x02019;s activation of pro-motility receptors in the gastrointestinal tract.</p>
      </sec>
      <sec id="article-18066.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although azithromycin is a generally well-tolerated, efficacious antimicrobial agent with many clinical indications, it is commonly inappropriately prescribed, particularly in the primary care setting. Several large retrospective cohort studies that demonstrated high levels of inappropriate antimicrobial prescribing overall singled out azithromycin as the most frequently misused drug.<xref ref-type="bibr" rid="article-18066.r66">[48]</xref><xref ref-type="bibr" rid="article-18066.r67">[49]</xref><xref ref-type="bibr" rid="article-18066.r68">[50]</xref><xref ref-type="bibr" rid="article-18066.r69">[51]</xref><xref ref-type="bibr" rid="article-18066.r70">[52]</xref>&#x000a0;Azithromycin is frequently prescribed when there is no clinical indication for antimicrobials and in many instances, azithromycin is not first-line therapy (eg, acute otitis media).<xref ref-type="bibr" rid="article-18066.r66">[48]</xref><xref ref-type="bibr" rid="article-18066.r70">[52]</xref>&#x000a0;Azithromycin is a frequent antimicrobial therapy prescribed in situations in which a narrow-spectrum beta-lactam (eg, amoxicillin) is the indicated first-line therapy (eg, acute otitis media).<xref ref-type="bibr" rid="article-18066.r66">[48]</xref>&#x000a0;Increasing resistance levels to azithromycin, particularly among <italic toggle="yes">S. pneumoniae</italic> isolates, make the widespread use of azithromycin for upper respiratory illness particularly concerning.<xref ref-type="bibr" rid="article-18066.r71">[53]</xref><xref ref-type="bibr" rid="article-18066.r72">[54]</xref>&#x000a0;Broad-spectrum antimicrobial use for upper respiratory infection is also associated with increased rates of adverse effects compared with narrow-spectrum agents.<xref ref-type="bibr" rid="article-18066.r73">[55]</xref></p>
        <p>One possible association with high rates of azithromycin prescription is patient-reported penicillin allergy.<xref ref-type="bibr" rid="article-18066.r75">[56]</xref>&#x000a0;Macrolides, particularly azithromycin, are preferred to beta-lactam drugs for many clinical indications. Researchers found 12.8% of patients in a large electronic medical records database have a penicillin allergy listed in&#x000a0;1 large cohort.<xref ref-type="bibr" rid="article-18066.r76">[57]</xref>&#x000a0;Patients with a reported penicillin allergy are as much as&#x000a0;4 times more likely to be prescribed a macrolide antimicrobial.<xref ref-type="bibr" rid="article-18066.r75">[56]</xref>&#x000a0;However, a detailed history of a patient&#x02019;s adverse reaction(s) to penicillin, paying close attention to features suggestive of IgE-mediated hypersensitivity (eg, urticaria, anaphylaxis), is often sufficient to clarify, and possibly remove, a listing of penicillin allergy.<xref ref-type="bibr" rid="article-18066.r77">[58]</xref>&#x000a0;Patients with more concerning histories may be administered allergy testing or referred to an allergy specialist. Lastly, providers should know the low cross-reactivity rates with cephalosporins&#x02014;especially third- and higher-generation agents&#x02014;and other beta-lactams in penicillin allergy.<xref ref-type="bibr" rid="article-18066.r78">[59]</xref></p>
        <p>Healthcare professionals in many different roles can contribute to appropriately using azithromycin and all antimicrobial agents. MDs, DOs, NPs, and PAs should prescribe azithromycin judiciously and use available evidence and society guidelines. Clinicians working with or supervising non-physician prescribers should ensure that all prescriptions accord with evidence and guideline-based practice.<xref ref-type="bibr" rid="article-18066.r68">[50]</xref>&#x000a0;Additionally, patients requesting antimicrobial therapy when it is not necessary or sharing concerns about drug allergies should be provided with education and appropriate follow-up. Nurses can be essential in addressing patient questions and facilitating continuity of care. Pharmacists are an invaluable resource for helping providers select the most appropriate antimicrobial agent, dosing, and duration of treatment. They can also help providers and patients avoid interactions between azithromycin and other drugs that affect the QTc interval. While azithromycin is a safe and effective antimicrobial drug, practitioners must prescribe it appropriately. Not only does the appropriate choice of antimicrobial therapy enhance treatment and support public health, but it avoids placing patients at unnecessary risk of adverse effects.</p>
      </sec>
      <sec id="article-18066.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18066&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18066">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18066/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18066">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18066.s11">
        <title>References</title>
        <ref id="article-18066.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girard</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Gootz</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Cimochowski</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Faiella</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Haskell</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Retsema</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1948</fpage>
            <page-range>1948-54</page-range>
            <pub-id pub-id-type="pmid">2830841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Retsema</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schelkly</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Manousos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bright</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borovoy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1939</fpage>
            <page-range>1939-47</page-range>
            <pub-id pub-id-type="pmid">2449865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakheit</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Al-Hadiya</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Abd-Elgalil</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin.</article-title>
            <source>Profiles Drug Subst Excip Relat Methodol</source>
            <year>2014</year>
            <volume>39</volume>
            <fpage>1</fpage>
            <page-range>1-40</page-range>
            <pub-id pub-id-type="pmid">24794904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dekate</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jayashree</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singhi</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Acute community acquired pneumonia in emergency room.</article-title>
            <source>Indian J Pediatr</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>9</issue>
            <fpage>1127</fpage>
            <page-range>1127-35</page-range>
            <pub-id pub-id-type="pmid">21541648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parnham</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Erakovic Haber</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giamarellos-Bourboulis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Perletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verleden</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin: mechanisms of action and their relevance for clinical applications.</article-title>
            <source>Pharmacol Ther</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>143</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-45</page-range>
            <pub-id pub-id-type="pmid">24631273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacifico</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scopetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ranucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pataracchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savignoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chiesa</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>1005</fpage>
            <page-range>1005-8</page-range>
            <pub-id pub-id-type="pmid">8849215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amaya-Tapia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aguirre-Avalos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Andrade-Villanueva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peredo-Gonz&#x000e1;lez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morf&#x000ed;n-Otero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Esparza-Ahumada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Noriega</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Once-daily azithromycin in the treatment of adult skin and skin-structure infections.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>31 Suppl E</volume>
            <fpage>129</fpage>
            <page-range>129-35</page-range>
            <pub-id pub-id-type="pmid">8396084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Mycobacterium avium Complex Disease.</article-title>
            <source>Microbiol Spectr</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28429679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waugh</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin in gonorrhoea.</article-title>
            <source>Int J STD AIDS</source>
            <year>1996</year>
            <volume>7 Suppl 1</volume>
            <fpage>2</fpage>
            <page-range>2-4</page-range>
            <pub-id pub-id-type="pmid">8652723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cusini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gomberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>2016 European guideline on Mycoplasma genitalium infections.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>1650</fpage>
            <page-range>1650-1656</page-range>
            <pub-id pub-id-type="pmid">27505296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Workowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bachmann</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Muzny</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zenilman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Sexually Transmitted Infections Treatment Guidelines, 2021.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2021</year>
            <month>Jul</month>
            <day>23</day>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>1</fpage>
            <page-range>1-187</page-range>
            <pub-id pub-id-type="pmid">34292926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Dyson</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Ingle</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Amir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aworh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Chattaway</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Crump</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Feasey</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Keddy</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Van Puyvelde</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Afolayan</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Anandan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ashton</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Basnyat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bavdekar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bogoch</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>De</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Ligt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diaz Guevara</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Dolecek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Francois Watkins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garrett</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Godbole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Greenhill</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hendriksen</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Heyderman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hooda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hormazabal</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ikhimiukor</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jinka</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kanteh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kapil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karkey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kariuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kingsley</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Koshy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lingegowda</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Luby</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Mackenzie</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Mashe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Msefula</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mutreja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagaraj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nagaraj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naseri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Nimarota-Brown</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Njamkepo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Okeke</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Perumal</surname>
                <given-names>SPB</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pragasam</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Qadri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>SIA</given-names>
              </name>
              <name>
                <surname>Rambocus</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Rasko</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robins-Browne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rongsen-Chandola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rutanga</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saigal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sajib</surname>
                <given-names>MSI</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shakya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shamanna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shastri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sikorski</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tagg</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tamrakar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tanmoy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Tupua</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Valcanis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Veeraraghavan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Weill</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dougan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Argim&#x000f3;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Aanensen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>KE</given-names>
              </name>
              <collab>Global Typhoid Genomics Consortium Group Authorship</collab>
            </person-group>
            <article-title>Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <italic>Salmonella</italic> Typhi genomes.</article-title>
            <source>Elife</source>
            <year>2023</year>
            <month>Sep</month>
            <day>12</day>
            <volume>12</volume>
            <pub-id pub-id-type="pmid">37697804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vanaudenaerde</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Verleden</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>De Vleeschauwer</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Willems-Widyastuti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Raemdonck</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Schoonis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nawrot</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Verleden</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.</article-title>
            <source>Eur Respir J</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>164</fpage>
            <page-range>164-72</page-range>
            <pub-id pub-id-type="pmid">20562124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baraket</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Upham</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial.</article-title>
            <source>Chest</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>262</fpage>
            <page-range>262-270</page-range>
            <pub-id pub-id-type="pmid">38431051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ukkonen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Renko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuitunen</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis.</article-title>
            <source>Pediatr Res</source>
            <year>2024</year>
            <month>May</month>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>1441</fpage>
            <page-range>1441-1447</page-range>
            <pub-id pub-id-type="pmid">38066246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Southern</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Solis-Moya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Macrolide antibiotics (including azithromycin) for cystic fibrosis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2024</year>
            <month>Feb</month>
            <day>27</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD002203</fpage>
            <pub-id pub-id-type="pmid">38411248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mogayzel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Naureckas</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hadjiliadis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoag</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lubsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hazle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sabadosa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>B</given-names>
              </name>
              <collab>Pulmonary Clinical Practice Guidelines Committee</collab>
            </person-group>
            <article-title>Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>01</day>
            <volume>187</volume>
            <issue>7</issue>
            <fpage>680</fpage>
            <page-range>680-9</page-range>
            <pub-id pub-id-type="pmid">23540878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lepore</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sikand</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Gadbaw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Telford</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Brassard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pearl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Azlanzadeh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spielman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Atovaquone and azithromycin for the treatment of babesiosis.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Nov</month>
            <day>16</day>
            <volume>343</volume>
            <issue>20</issue>
            <fpage>1454</fpage>
            <page-range>1454-8</page-range>
            <pub-id pub-id-type="pmid">11078770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunne</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shukla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valecha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Dev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mohapatra</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Lakhani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India.</article-title>
            <source>J Infect Dis</source>
            <year>2005</year>
            <month>May</month>
            <day>15</day>
            <volume>191</volume>
            <issue>10</issue>
            <fpage>1582</fpage>
            <page-range>1582-8</page-range>
            <pub-id pub-id-type="pmid">15838784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiojiri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kinai</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Teruya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>841</fpage>
            <page-range>841-843</page-range>
            <pub-id pub-id-type="pmid">30882331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <article-title>Corrigendum to: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <page-range>172-173</page-range>
            <pub-id pub-id-type="pmid">33960362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Auwaerter</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Branda</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Lantos</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rips</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Vannier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Wormser</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Jan</month>
            <day>27</day>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>e49</fpage>
            <page-range>e49-e64</page-range>
            <pub-id pub-id-type="pmid">33252652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lagier</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Parola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Meddeb</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mailhe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doudier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Courjon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giordanengo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Tissot Dupont</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Honor&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chabri&#x000e8;re</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>La Scola</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rolain</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brouqui</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Raoult</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>105949</fpage>
            <pub-id pub-id-type="pmid">32205204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lagier</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Parola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Meddeb</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sevestre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mailhe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doudier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aubry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amrane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hocquart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eldin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Finance</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Tissot-Dupont</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Honor&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Million</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>La Scola</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Veit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jacquier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deharo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Drancourt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Rolain</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brouqui</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Raoult</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.</article-title>
            <source>Travel Med Infect Dis</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>34</volume>
            <fpage>101663</fpage>
            <pub-id pub-id-type="pmid">32289548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arabi</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Deeb</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Hameed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mandourah</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Almekhlafi</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sindi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Al-Omari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shalhoub</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mady</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alraddadi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Almotairi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Khatib</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abdulmomen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qushmaq</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Solaiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al-Aithan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Raddadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ragab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Harthy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kharaba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dabbagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Balkhy</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Merson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>FG</given-names>
              </name>
              <collab>Saudi Critical Care Trials group</collab>
            </person-group>
            <article-title>Macrolides in critically ill patients with Middle East Respiratory Syndrome.</article-title>
            <source>Int J Infect Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>81</volume>
            <fpage>184</fpage>
            <page-range>184-190</page-range>
            <pub-id pub-id-type="pmid">30690213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pitrez</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Luisi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Mello</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Gerhardt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferlini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Daros</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Marostica</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial.</article-title>
            <source>J Pediatr</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>161</volume>
            <issue>6</issue>
            <fpage>1104</fpage>
            <page-range>1104-8</page-range>
            <pub-id pub-id-type="pmid">22748516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Echeverr&#x000ed;a-Esnal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin-Ontiyuelo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Navarrete-Rouco</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>De-Antonio Cusc&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferr&#x000e1;ndez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Horcajada</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Grau</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin in the treatment of COVID-19: a review.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-163</page-range>
            <pub-id pub-id-type="pmid">32853038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Fesik</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Doran</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>426</fpage>
            <page-range>426-31</page-range>
            <pub-id pub-id-type="pmid">2159256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeli&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antolovi&#x00107;</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>5</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">27598215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neu</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Clinical microbiology of azithromycin.</article-title>
            <source>Am J Med</source>
            <year>1991</year>
            <month>Sep</month>
            <day>12</day>
            <volume>91</volume>
            <issue>3A</issue>
            <fpage>12S</fpage>
            <page-range>12S-18S</page-range>
            <pub-id pub-id-type="pmid">1656736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sidhu</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Nkrumah</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Sacchettini</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fidock</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.</article-title>
            <source>J Biol Chem</source>
            <year>2007</year>
            <month>Jan</month>
            <day>26</day>
            <volume>282</volume>
            <issue>4</issue>
            <fpage>2494</fpage>
            <page-range>2494-504</page-range>
            <pub-id pub-id-type="pmid">17110371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biddau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sheiner</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Targeting the apicoplast in malaria.</article-title>
            <source>Biochem Soc Trans</source>
            <year>2019</year>
            <month>Aug</month>
            <day>30</day>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>973</fpage>
            <page-range>973-983</page-range>
            <pub-id pub-id-type="pmid">31383817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verleden</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Vanaudenaerde</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Van Raemdonck</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Sep</month>
            <day>01</day>
            <volume>174</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-70</page-range>
            <pub-id pub-id-type="pmid">16741151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarique</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tuladhar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kelk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Begum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stow</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wainwright</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sly</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Fantino</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic Fibrosis.</article-title>
            <source>Cells</source>
            <year>2024</year>
            <month>Jan</month>
            <day>16</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38247856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menzel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akbarshahi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bjermer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Uller</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Jun</month>
            <day>28</day>
            <volume>6</volume>
            <fpage>28698</fpage>
            <pub-id pub-id-type="pmid">27350308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ebrahimi Samangani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kargari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiani Nejad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yashmi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Motahar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Khoshnood</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action, resistance, synergism, and clinical implications of azithromycin.</article-title>
            <source>J Clin Lab Anal</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>e24427</fpage>
            <pub-id pub-id-type="pmid">35447019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;ffler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koeppe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paeske</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of azithromycin in normal and impaired renal function.</article-title>
            <source>Infection</source>
            <year>1995</year>
            <season>Nov-Dec</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>356</fpage>
            <page-range>356-61</page-range>
            <pub-id pub-id-type="pmid">8655206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drew</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gallis</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications.</article-title>
            <source>Pharmacotherapy</source>
            <year>1992</year>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-73</page-range>
            <pub-id pub-id-type="pmid">1319048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughn</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Community-Acquired Pneumonia: A Review.</article-title>
            <source>JAMA</source>
            <year>2024</year>
            <month>Oct</month>
            <day>15</day>
            <volume>332</volume>
            <issue>15</issue>
            <fpage>1282</fpage>
            <page-range>1282-1295</page-range>
            <pub-id pub-id-type="pmid">39283629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>e103</fpage>
            <page-range>e103-e119</page-range>
            <pub-id pub-id-type="pmid">30134425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Practice Bulletin No. 135: Second-trimester abortion.</article-title>
            <source>Obstet Gynecol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>121</volume>
            <issue>6</issue>
            <fpage>1394</fpage>
            <page-range>1394-1406</page-range>
            <pub-id pub-id-type="pmid">23812485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <article-title>Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217.</article-title>
            <source>Obstet Gynecol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>135</volume>
            <issue>3</issue>
            <fpage>e80</fpage>
            <page-range>e80-e97</page-range>
            <pub-id pub-id-type="pmid">32080050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <chapter-title>Azithromycin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioannidis</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Contopoulos-Ioannidis</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>677</fpage>
            <page-range>677-89</page-range>
            <pub-id pub-id-type="pmid">11679557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arbogast</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin and the risk of cardiovascular death.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>May</month>
            <day>17</day>
            <volume>366</volume>
            <issue>20</issue>
            <fpage>1881</fpage>
            <page-range>1881-90</page-range>
            <pub-id pub-id-type="pmid">22591294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Svanstr&#x000f6;m</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hviid</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use of azithromycin and death from cardiovascular causes.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>May</month>
            <day>02</day>
            <volume>368</volume>
            <issue>18</issue>
            <fpage>1704</fpage>
            <page-range>1704-12</page-range>
            <pub-id pub-id-type="pmid">23635050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vuppalanchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Clinical and histologic features of azithromycin-induced liver injury.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>369</fpage>
            <page-range>369-376.e3</page-range>
            <pub-id pub-id-type="pmid">25111234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barboza</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Okun</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Moshiree</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <volume>16</volume>
            <issue>16</issue>
            <fpage>2449</fpage>
            <page-range>2449-64</page-range>
            <pub-id pub-id-type="pmid">26374094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nappe</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Goren-Garcia</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit.</article-title>
            <source>Am J Emerg Med</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>676.e1</fpage>
            <page-range>676.e1-3</page-range>
            <pub-id pub-id-type="pmid">26194400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pecorari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pantano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>De Martino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Novembre</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin anaphylaxis in children.</article-title>
            <source>Int J Immunopathol Pharmacol</source>
            <year>2014</year>
            <season>Jan-Mar</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">24674687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dascal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barkun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suissa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection.</article-title>
            <source>CMAJ</source>
            <year>2008</year>
            <month>Oct</month>
            <day>07</day>
            <volume>179</volume>
            <issue>8</issue>
            <fpage>767</fpage>
            <page-range>767-72</page-range>
            <pub-id pub-id-type="pmid">18838451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuntz</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chrischilles</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Pendergast</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Herwaldt</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Polgreen</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study.</article-title>
            <source>BMC Infect Dis</source>
            <year>2011</year>
            <month>Jul</month>
            <day>15</day>
            <volume>11</volume>
            <fpage>194</fpage>
            <pub-id pub-id-type="pmid">21762504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshpande</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pasupuleti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thota</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rolston</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sferra</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Donskey</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Community-associated Clostridium difficile infection and antibiotics: a meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>9</issue>
            <fpage>1951</fpage>
            <page-range>1951-61</page-range>
            <pub-id pub-id-type="pmid">23620467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaroff</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Cheetham</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Palmetto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Almers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Quesenberry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gatto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Corley</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Association of Azithromycin Use With Cardiovascular Mortality.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>e208199</fpage>
            <pub-id pub-id-type="pmid">32585019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westphal</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-95</page-range>
            <pub-id pub-id-type="pmid">11012550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flockhart</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Drici</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kerbusch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soukhova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pearle</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Mahal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Babb</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-24</page-range>
            <pub-id pub-id-type="pmid">10831018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouqui&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deslandes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Renaud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dailly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haloun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jolliet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-30</page-range>
            <pub-id pub-id-type="pmid">21169852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Digiacinto</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kook</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>2226</fpage>
            <page-range>2226-37</page-range>
            <pub-id pub-id-type="pmid">21480191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aubert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Culty</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zidane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bigot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lebdai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment.</article-title>
            <source>Front Oncol</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>1240378</fpage>
            <pub-id pub-id-type="pmid">38525411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergeron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Granata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chevallier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabrizi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Labussiere-Wallet</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chantepie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bay</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Thiebaut-Bertrand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thepot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Contentin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fornecker</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Maillard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Risso</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berceanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blaise</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peffault de La Tour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Coiteux</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Soci&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <collab>ALLOZITHRO Study Investigators</collab>
            </person-group>
            <article-title>Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Aug</month>
            <day>08</day>
            <volume>318</volume>
            <issue>6</issue>
            <fpage>557</fpage>
            <page-range>557-566</page-range>
            <pub-id pub-id-type="pmid">28787506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Thackray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lubsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hellinga</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title><italic>K</italic>ey Potentially <italic>I</italic>nappropriate <italic>D</italic>rugs in Pediatrics: The KIDs List.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-191</page-range>
            <pub-id pub-id-type="pmid">32265601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease.</article-title>
            <source>Clin Infect Dis</source>
            <year>1997</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>958</fpage>
            <page-range>958-64</page-range>
            <pub-id pub-id-type="pmid">9142801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koletar</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cynamon</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>2869</fpage>
            <page-range>2869-72</page-range>
            <pub-id pub-id-type="pmid">10582873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eckardt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bruns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Biertz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramtin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reinsch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fabritz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Breithardt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haverkamp</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>303</volume>
            <issue>1</issue>
            <fpage>218</fpage>
            <page-range>218-25</page-range>
            <pub-id pub-id-type="pmid">12235254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury - Types and Phenotypes.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jul</month>
            <day>18</day>
            <volume>381</volume>
            <issue>3</issue>
            <fpage>264</fpage>
            <page-range>264-273</page-range>
            <pub-id pub-id-type="pmid">31314970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming-Dutra</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Demirjian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartoces</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Variations in Antibiotic and Azithromycin Prescribing for Children by Geography and Specialty-United States, 2013.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-58</page-range>
            <pub-id pub-id-type="pmid">28746259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chua</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Jan</month>
            <day>16</day>
            <volume>364</volume>
            <fpage>k5092</fpage>
            <pub-id pub-id-type="pmid">30651273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shively</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Buehrle</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Inappropriate Antibiotic Prescribing in Primary Care Clinics within a Veterans Affairs Health Care System.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">29967028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sellick</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mergenhagen</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic stewardship targets in the outpatient setting.</article-title>
            <source>Am J Infect Control</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>8</issue>
            <fpage>858</fpage>
            <page-range>858-863</page-range>
            <pub-id pub-id-type="pmid">30862373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Havers</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gaglani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Nowalk</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Monto</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Belongia</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Flannery</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons.</article-title>
            <source>JAMA Netw Open</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>e180243</fpage>
            <pub-id pub-id-type="pmid">30646067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Critchley</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Traczewski</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tillotson</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Janjic</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>7</issue>
            <fpage>2639</fpage>
            <page-range>2639-43</page-range>
            <pub-id pub-id-type="pmid">18443117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karlowsky</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Thornsberry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Critchley</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Evangelista</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Sahm</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>1790</fpage>
            <page-range>1790-7</page-range>
            <pub-id pub-id-type="pmid">12760850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerber</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Localio</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Szymczak</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barkman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Odeniyi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Conaboy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zaoutis</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Fiks</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Dec</month>
            <day>19</day>
            <volume>318</volume>
            <issue>23</issue>
            <fpage>2325</fpage>
            <page-range>2325-2336</page-range>
            <pub-id pub-id-type="pmid">29260224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A growing battlefield in the war against biofilm-induced antimicrobial resistance: insights from reviews on antibiotic resistance.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2023</year>
            <volume>13</volume>
            <fpage>1327069</fpage>
            <pub-id pub-id-type="pmid">38188636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blumenthal</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Walensky</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Risk of meticillin resistant <italic>Staphylococcus aureus</italic> and <italic>Clostridium difficile</italic> in patients with a documented penicillin allergy: population based matched cohort study.</article-title>
            <source>BMJ</source>
            <year>2018</year>
            <month>Jun</month>
            <day>27</day>
            <volume>361</volume>
            <fpage>k2400</fpage>
            <pub-id pub-id-type="pmid">29950489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dhopeshwarkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Goss</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Topaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slight</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Drug allergies documented in electronic health records of a large healthcare system.</article-title>
            <source>Allergy</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>9</issue>
            <fpage>1305</fpage>
            <page-range>1305-13</page-range>
            <pub-id pub-id-type="pmid">26970431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenoy</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Macy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Management of Penicillin Allergy: A Review.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>321</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-199</page-range>
            <pub-id pub-id-type="pmid">30644987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18066.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valluzzi</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maggioletti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quaratino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gaeta</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1662</fpage>
            <page-range>1662-1672</page-range>
            <pub-id pub-id-type="pmid">29408440</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
